Clinical Trials Logo
  1. Home
  2. Dry Eye
  3. NCT05965778
  4. Details
NCT05965778 Clinical Trial

Comparison of the Performance and Safety of T2769 Versus Vismed® Multi in the Treatment of Moderate to Severe Dry Eye Syndrome

Dry Eye Clinical Trial

Official title:
Comparison of the Performance and Safety of T2769 Versus Vismed® Multi in the Treatment of Moderate to Severe Dry Eye Syndrome

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT05965778
Other study ID # LT2769-002
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date October 2, 2023
Est. completion date August 2024

Study information
Verified date July 2023
Source Laboratoires Thea
Contact Corentin LE CAMUS
Phone +33473981436
Email Corentin.LECAMUS@theapharma.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To demonstrate the non-inferiority of T2769 compared to Vismed® Multi in terms of total ocular surface staining (Oxford score) after 35 days of treatment. To evaluate the performance and safety of T2769 versus Vismed® Multi.

Recruitment information / eligibility
Status Recruiting
Enrollment 226
Est. completion date August 2024
Est. primary completion date August 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Informed consent signed and dated (obtained prior to initiating any procedures). - Patient aged =18 years old. - Known dry eye syndrome requiring artificial tears for at least the last 3 months prior to screening visit. - Surface Disease Index (OSDI) Score = 23. - Ocular discomfort evaluated by VAS = 40 mm. Exclusion Criteria: - Far best-corrected visual acuity (BCVA) =+0.7 LogMar (e.g., =0.2 in decimal value or =20/100 Snellen equivalent or =50 (ETDRS) letters Early Treatment Diabetic Retinopathy Study). - Severe blepharitis according to the judgment of the investigator - Dry eye associated with at least one of the following diseases/symptoms: ocular rosacea, Pterygium, Eyelid malposition, Corneal dystrophy, Ocular neoplasia, Filamentous keratitis, Corneal neovascularisation, Orbital radiotherapy, Cataract, Retinal disease.

Study Design

Related Conditions & MeSH terms

Intervention

Device:
• T2769
T2769: sodium hyaluronate, Trehalose, Naaga in a 12.5 mL ABAK® multi-dose bottle.
• Vismed® Multi
Hyaluronic acid

Locations
Country Name City State
France Gabriel-Montpied University Hospital Clermont-Ferrand

Sponsors (1)
Lead Sponsor Collaborator
Laboratoires Thea

Country where clinical trial is conducted

France, 

Outcome
Type Measure Description Time frame Safety issue
Primary Change from baseline (Day 1) in total ocular surface staining grade according to Oxford 0-15 grading scheme. The primary endpoint is the change from baseline (Day 1) in total ocular surface staining grade according to Oxford Scale (Oxford Scheme) 0-15 grading scheme at D36 in the study eye. Minimum value is 0 (better outcome) and maximum value is 15 (worse outcome) Oxford 0-15 grading scheme: is assessed at Day 1 and Day 36
See also
  Status Clinical Trial Phase
Completed NCT06159569 - Performance and Tolerability of the Medical Device LACRIACT N/A
Completed NCT05027087 - The Effect of a Novel Blueberry Supplement on Dry Eye Disease Phase 3
Completed NCT05102409 - An Exploratory Clinical Trial to Assess Safety and Tolerability in Subjects With Dry Eye Disease Phase 2
Completed NCT04081610 - Clinical Trial to Evaluate the Safety and Tolerability of Lagricel® Ofteno Multi-dose Ophthalmic Solution Phase 1
Completed NCT05062564 - Efficacy of LipiFlow in Patients Affected by Meibomian Gland Dysfunction in Reducing Post-cataract Surgery Dry Eye N/A
Completed NCT05825599 - PMCF Study to Evaluate Performance and Safety of "HPMC-based Eyedrops" Used to Relieve Dry Eye Symptoms N/A
Completed NCT03418727 - Dry Eye Disease Study With Brimonidine Phase 2
Active, not recruiting NCT04425551 - Effect of Micropulse Laser on Dry Eye Disease Due to Meibomian Gland Dysfunction N/A
Recruiting NCT04527887 - Intracanalicular Dexamethasone Insert for the Treatment of Inflammation and Discomfort in Dry Eye Disease (DEcIDED) Phase 4
Not yet recruiting NCT06379685 - Study to Evaluate the Safety and Tolerability of PRO-190 Ophthalmic Solution Compared to Systane Ultra® on the Ocular Surface. Phase 1
Active, not recruiting NCT05618730 - Safety, Tolerability, Plug Retention and Preliminary Efficacy of Tacrolimus-loaded Punctal Plug in Patients With Moderate to Severe Dry Eye Disease - Cohort B Phase 1
Completed NCT04553432 - Dry Eye OmniLenz Application of Omnigen Research Study Phase 4
Recruiting NCT04109170 - Dry Eye Evaluation System Based on Bioinformatics
Completed NCT04105842 - Refitting Daily Disposable Contact Lens Wearers With Dry Eye Disease With A Different Daily Disposable Lens Type N/A
Completed NCT05505292 - Lifitegrast 5% for the Treatment of Dry Eye In Habitual Soft Contact Lens Wearers Phase 4
Completed NCT04668131 - Study on Curative Effect and Mechanism of Acupuncture on Neuropathic Pain in Dry Eye Disease N/A
Completed NCT06176651 - Evaluation of Miebo (Perfluorohexyloctane) Eyedrops in Habitual Contact Lens Wearers Phase 4
Completed NCT02235259 - Efficacy and Safety of XG-104 for the Treatment of Dry Eye Phase 2
Not yet recruiting NCT02218827 - Topical Steroid Treatment For Dry Eye N/A
Completed NCT01959854 - Efficacy of Topical 0.2% Xanthan Gum in Patients With Dry Eye N/A